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Abstract
The diagnostic impact of PCR-based detection was compared to single-serum IgM antibody measurement and IgG antibody seroconver-
sion during an outbreak of Chlamydophila pneumoniae in a military community. Nasopharyngeal swabs for PCR-based detection, and
serum, were obtained from 127 conscripts during the outbreak. Serum, drawn many months before the outbreak, provided the baseline
antibody status. C. pneumoniae IgM and IgG antibodies were assayed using microimmunoﬂuorescence (MIF), enzyme immunoassay (EIA)
and recombinant ELISA (rELISA). Two reference standard tests were applied: (i) C. pneumoniae PCR; and (ii) assay of C. pneumoniae IgM
antibodies, deﬁned as positive if ‡2 IgM antibody assays (i.e. rELISA with MIF and/or EIA) were positive. In 33 subjects, of whom two
tested negative according to IgM antibody assays and IgG seroconversion, C. pneumoniae DNA was detected by PCR. The sensitivities
were 79%, 85%, 88% and 68%, respectively, and the speciﬁcities were 86%, 84%, 78% and 93%, respectively, for MIF IgM, EIA IgM,
rELISA IgM and PCR. In two subjects, acute infection was diagnosed on the basis of IgG antibody seroconversion alone. The sensitivity
of PCR detection was lower than that of any IgM antibody assay. This may be explained by the late sampling, or clearance of the organ-
ism following antibiotic treatment. The results of assay evaluation studies are affected not only by the choice of reference standard
tests, but also by the timing of sampling for the different test principles used. On the basis of these ﬁndings, a combination of nasophar-
yngeal swabbing for PCR detection and speciﬁc single-serum IgM measurement is recommended in cases of acute respiratory
C. pneumoniae infection.
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Introduction
Diagnosing acute respiratory Chlamydophila pneumoniae infec-
tion is a challenge. Although some patients present with a
chronic cough or atypical pneumonia [1], most
C. pneumoniae infections are asymptomatic or mild, and
remain unrecognized [2–4]. Establishing a diagnosis of
C. pneumoniae is important because of its impact on antibio-
tic treatment of symptomatic individuals, and in order to
contain outbreaks. With regard to the detection of
C. pneumoniae, many studies have shown poor agreement
between the results obtained by culture, PCR and serology
[3–6], whereas others have found good agreement [7,8].
The diagnostic accuracy of the microimmunoﬂuorescence
(MIF) test has also been questioned [4,5,9–13]. Following pri-
mary infection, IgM antibodies detectable by MIF may not
appear before 3 weeks after onset of illness, and IgG antibo-
dies may not reach levels detectable by MIF for 6–8 weeks
[14].
In contrast, recombinant ELISA (rELISA) measures Chlamy-
dia genus-speciﬁc lipopolysaccharide antibodies, starting at
the onset of C. pneumoniae symptoms [8,13,14]. Thus, rELISA
has been reported to be very sensitive but also less speciﬁc,
giving rise to false-positive results [11,15]. The recently
introduced C. pneumoniae-speciﬁc enzyme immunoassay (EIA)
has been evaluated, with promising results [15].
Generally, the detection of a speciﬁc antibody response is
regarded as evidence of infection. Likewise, the direct detec-
tion of the intracellular bacterium C. pneumoniae in respira-
tory samples is considered to be sufﬁcient evidence for the
diagnosis of C. pneumoniae respiratory tract infection.
These two very different diagnostic principles—antibody
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measurement and detection of DNA—may yield different
time-dependent results during infection, as observed in pneu-
monia caused by other atypical community-acquired patho-
gens [16–18]. We postulate that during C. pneumoniae
infection, PCR assays detect DNA in clinical samples earlier
than serological assays detect an IgM antibody response.
Consequently, in assay evaluation studies, the choice of
reference standards and the timing of sampling will inﬂuence
the results (Fig. 1).
The aim of this study was to compare PCR-based detec-
tion of C. pneumoniae DNA with three different
C. pneumoniae antibody assays. Access to stored frozen sera,
drawn 8–11 months before the outbreak, provided an indivi-
dual baseline or pre-outbreak antibody status, which was of
great advantage when differentiating between the IgM and
IgG antibody responses during the outbreak and the baseline
seroreactivity.
Materials and Methods
Subjects and study design
The outbreak, lasting from April to the end of June 2000,
occurred among approximately 2000 conscripts stationed in
two military camps in Troms county of northern Norway.
A serum sample (‘pre-outbreak serum’) was drawn routinely
from each conscript upon enrolment in August 1999. One
mL was frozen in polystyrene containers, which were sealed
with parafﬁn wax and stored at )20C at the Norwegian
Armed Forces Institute of Microbiology, as reported pre-
viously [2]. A second blood sample (‘outbreak serum’) was
drawn from the eligible conscripts during the outbreak. The
sera were analysed 1.5–2 years after the outbreak. Shortly
before analysis, the pre-outbreak sera were thawed and
shipped overnight to the laboratory in charge of the analyses.
Subjects were eligible for the study if a pre-outbreak
serum, an outbreak serum and a nasopharyngeal swab sam-
ple were available. The nasopharyngeal samples were taken
only once, at the same time as the outbreak sera. Clinical ill-
ness and respiratory tract symptoms were the reasons for
nasopharyngeal sampling for PCR-based detection and sero-
logical testing, initially for several respiratory pathogens, in
order to ﬁnd the causative infectious agent. Conscripts from
the same unit with mild symptoms or without symptoms
were also asked to submit specimens. Information regarding
age, gender, antimicrobial treatment and respiratory symp-
toms were obtained in interviews and/or from medical
records. The conscripts gave verbal informed consent to
participate in the study, which was approved and recom-
mended by the Norwegian armed forces.
Deﬁnitions
The case deﬁnition of acute respiratory C. pneumoniae infec-
tion was that of a conscript living in a closed military com-
munity during the outbreak with: (i) a positive test result
according to the deﬁnitions; and (ii) a negative IgM serology
ﬁnding at baseline. Irrespective of respiratory symptoms,
these conscripts represent the test-positive group. Taking
into account that PCR detection of C. pneumoniae DNA is a
test principle that is different from that of the IgM and IgG
antibody assays, two reference standards were applied: (i)
PCR results; and (ii) IgM antibody results.
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FIG. 1. The theoretical dynamics of PCR and serology results in acute Chlamydophila pneumoniae infection. The test outcome will depend on
the choice of the reference standard. If serum IgM antibody is chosen as the reference standard, a positive PCR result is taken as ‘false-positive’
during the ﬁrst few weeks following onset of illness before the IgM antibody test turns positive (phase 1). Normally, PCR becomes negative after
some days to months, considered as ‘false-negative’ (phase 3). If PCR is applied as the reference standard, the IgM antibody is ‘false-negative’ in
phase 1 and appears ‘false-positive’ in phase 3. Only in phase 2 will the results agree. Chlamydia genus-speciﬁc IgM antibodies is ﬁrst and may
be present in the acute-phase serum, whereas microimmunoﬂuorescence (speciﬁc) IgM antibodies may not appear for 3 weeks; IgG, serum IgG
antibodies may not reach diagnostic titre levels for 6–8 weeks [14].
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The IgM antibody reference standard was considered posi-
tive when ‡2 independent IgM assays were positive. As MIF
and EIA assays are produced by the same manufacturer and
employ an identical chlamydial antigen, the deﬁnition
excludes the combination MIF/EIA IgM positivity.
IgG seroconversion was deﬁned as: (i) a ‡3-fold OD
increase of rELISA IgG in combination with (ii) a ‡4-fold titre
increase of MIF IgG and/or (iii) a ‡1.5-fold increase of EIA
IgG if the ﬁrst value was <130 enzyme immunounits (EIU) or
a ‡1.3-fold increase if the ﬁrst value was >130 EIU.
A true-negative result was deﬁned as any result that was
negative according to both PCR and IgG seroconversion, and
<2 IgM antibody assays yielding positive results (test-negative
group). The combination of positive results according to
MIF/EIA IgM and/or IgG seroconversion was also deﬁned as
negative for the reasons mentioned above. For calculation of
C. pneumoniae antibody prevalence in the 127 conscripts
before and during the outbreak, samples were deﬁned as
positive when ‡2 IgM and/or ‡2 IgG antibody assays were
positive.
Nasopharyngeal swabs and PCR-based detection
A thin, ﬂexible metallic swab with a rayon tip was inserted
through one of the nostrils into the nasopharyngeal tract for
15 s before being placed in 2.5 mL of transport medium
(medium essential medium (Gibco), fetal bovine serum,
Hepes 1 M, gentamicin 50 mg/L, adjusted to pH 7.1–7.3).
Vials were sent to the laboratory overnight at ambient
temperature, and stored at 4C for 0–4 days until PCR ana-
lysis. A modiﬁed nested C. pneumoniae PCR with outer pri-
mers (CP1 and CP2) speciﬁc for the major outer membrane
protein genes (ompA) of C. pneumoniae and Chlamydia psittaci
was performed as described by Tong and Sillis [19]. The
outer primers (CP1, 5¢-TTACAAGCCTTGCCTGTAGG-3¢;
and CP2, 5¢-GCGATCCCAAATGTTTAAGGC-3¢) allowed
ampliﬁcation of a 333-bp product, and the internal primers
(CPC, 5¢-TTATTAATTGATGGTACAATA-3¢; and CPD,
5¢-ATCTACGGCAGTAGTATAGTT-3¢) allowed ampliﬁca-
tion of a 207-bp product. Internal primers are considered to
be highly speciﬁc for C. pneumoniae [20]. The sample was
vortexed for 1 min, and then the rayon tip was discarded
before the sample was centrifuged at 2500 g for 10 min.
After removal of 1.5 mL of the supernatant, the sample was
vortexed and divided into two aliquots of 200 lL each, one
of which was processed as a native sample, and the other of
which was spiked with 2000 copies/mL of C. pneumoniae
DNA. The DNA extraction was performed using the manual
QIAmp DNA mini kit or the automatic QIAmp 96 DNA
Blood BioRobot 9604 kit (Qiagen Inc., Valencia, CA, USA),
according to the manufacturer’s instructions. PCR was per-
formed with one of three PCR systems: PE 9600, PE 9700
or PE 2400 (PE Applied Biosystems, Foster city, CA, USA).
In the rack, each tube of native sample was preceded by a
tube with PCR buffer and followed by the spiked sample and
a negative sample containing ddH2O. For the ﬁrst PCR, the
thermal cycling was initiated at 95C for 5 min, and this was
followed by 20 cycles, each consisting of three 1-min peri-
ods: denaturation at 94C; annealing at 65C; and elongation
at 72C. The annealing temperature was lowered by 0.5C
every cycle to 55C. The next 20 cycles were carried out
with cycles of 30 s at 94C, 55C and 72C. The second
PCR consisted of 30 cycles with incubation at 95C for
5 min, followed by 94C for 15 s and two periods at 50C
and 72C, each for 30 s. The ampliﬁcation products were
separated by agarose (3%) gel electrophoresis for 1 h in buf-
fer (0.75 · phosphate-buffered saline) and visualized by ethi-
dium bromide staining. The detection limit of the second
PCR was 5 fg, corresponding to approximately ﬁve genome
copies. The reagents were prepared in a clean room, and
the principle of unidirectional workﬂow was applied, with
separate rooms and separate ventilation for each PCR.
Serological assays
During the C. pneumoniae outbreak, the MIF test was per-
formed routinely and was repeated using paired sera, in con-
junction with two other antibody assays. On the basis of
preliminary MIF results, equal numbers of positive and nega-
tive samples were analysed within the same run. Paired sera
from each subject within each run were randomized and
blindly analysed. The sera were assayed for IgM and IgG anti-
bodies with three commercially available tests that are based
on different immunoassay principles, adhering strictly to the
manufacturers’ instructions concerning protocol, calculation
and reporting of results (Table 1).
With the MIF test (Labsystems, Helsinki, Finland), sera
were screened for IgM antibody detection at a 1 : 8 dilution.
Reactive sera were further diluted 1 : 16, 1 : 32 and 1 : 64.
The IgG analyses started with screening at 1 : 16 and, if reac-
tive, were diluted two-fold from 1 : 32 to 1 : 512.
The calculation for the EIA test (Labsystems) was per-
formed according to: ODsample  ODblank=ODcalibrator 
ODblank  k where k is a constant.
In order to compare EIA with MIF, the manufacturer
applies a constant (k = 130) in the calculation of IgG anti-
body values, and recommends reporting results in enzyme
immunounits (EIU). Samples with absorbance higher than
that of the positive control were further diluted 1 : 200,
1 : 400 and 1 : 800 for IgG.
The rELISA test applies recombinant genus-speciﬁc Chla-
mydia antigens (Medac, Hamburg, Germany). After the blank
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was subtracted from all values, the cut-off was calculated as
follows: OD of the negative control +0.37 for IgM and +0.32
for IgG. The cut-off index is deﬁned as: ODsample/ODcut-off.
Samples with a cut-off index >1.15 for IgM and >1.10 for IgG
were considered positive. Samples with OD >2.0 were
further diluted 1 : 800 for IgG.
Statistical methods
Sensitivity and speciﬁcity were calculated by SPSS 14.0.1 for
Windows. Differences in duration of illness were calculated
by the Mann–Whitney U-test. Cochran’s Q-test was used to
compare the detection rates of more than two assays. The
strength of agreement between two tests was calculated
with kappa (j) values [21]. All values were dichotomized into
positive or negative, except when testing the correlation
between two IgM antibody assays by Spearman’s rank corre-
lation; p <0.05 (two-tailed) was considered to be statistically
signiﬁcant. The linear regression of cumulative sensitivity of
the PCR and IgM antibody assays were calculated with Graph
Pad Prism 3.00.
Results
Classiﬁcation
Samples were obtained from 127 conscripts (123 males and
four females with mean age (SD) of 20.2 years (1.03), range
18.7–27.1 years). In the test-positive group (n = 48), respira-
tory symptoms were reported by 44 conscripts (100%; no
data, n = 4). Antibiotics were prescribed in 37 cases (88%;
no data, n = 6). The corresponding ﬁgures in the test-nega-
tive group (n = 79) were 54 (77%; no data, n = 9) with
respiratory symptoms and 14 (26%; no data, n = 25) who
received antibiotics.
PCR and serology
Among the 127 conscripts studied, 33 were PCR-positive, 40
were IgM antibody-seropositive and 12 demonstrated IgG
seroconversion, according to the study criteria (Table 2).
Regarding the IgM antibody-positive and seroconversion sam-
ples, 29 cases were PCR-positive and 13 were PCR-negative.
The median interval from start of symptoms until sampling
was 18 days (range 3–45 days) in the PCR-positive group
and 47.0 days (range 12–76 days) in the PCR-negative group.
The difference between the intervals was statistically signiﬁ-
cant (p 0.01) (Fig. 2). The median for all positive samples
was 24 days. The detection rate of each IgM assay differed
signiﬁcantly from that of the others and from those of PCR.
The strength of agreement between any two of the assays
(one PCR and three IgM assays) varied from ‘moderate’
(j = 0.41–0.60) to ‘good’ (j = 0.61–0.80) [21]: PCR vs.
rELISA, j = 0.56; PCR vs. MIF, j = 0.61; PCR vs. EIA,
j = 0.63; MIF vs. rELISA, j = 0.67; EIA vs. rELISA, j = 0.71;
and MIF vs. EIA, j = 0.78.
The strength of agreement was also tested for the follow-
ing combinations: PCR vs. ‡2 IgM positive, j = 0.64; PCR vs.
‡2 IgM and IgG seroconversion, j = 0.65; PCR vs. IgG sero-
conversion, j = 0.25. (j = 0.21–0.40 is interpreted as ‘poor’
agreement.) MIF and EIA IgM antibody assay results corre-
lated signiﬁcantly (r = 0.80, p <0.01). Two subjects tested
exclusively IgM-positive using MIF, and two tested IgM-posi-
tive using EIA. Seven subjects tested exclusively IgM-positive
using rELISA. Two subjects tested positive using PCR alone.
Their nasopharyngeal and blood samples were taken shortly
after onset of illness, at days 11 and 14. Tables 3 and 4 show
sensitivity, speciﬁcity and positive predictive values.
Time-dependent cumulative sensitivities
The cumulative sensitivity of C. pneumoniae PCR was higher
than that of the IgM antibody assay during the ﬁrst weeks
after onset of illness, but decreased with time. The cumula-
tive sensitivity of the IgM antibody assays increased. The
regression line of PCR was y = )2.58x + 96 (r = 0.76,
p 0.03) and that of the IgM antibody assays was
y = 1.84x + 73 (r = 0.90, p 0.002). The lines intersect at
5 weeks (Fig. 3).
IgG antibody seroconversion
In eight cases, IgG seroconversion was demonstrated with
the combination of rELISA and EIA, and seroconversion
according to all three IgG assays was seen in four cases.
TABLE 1. Cut-off values for serological Chlamydophila
pneumoniae IgM and IgG antibody assays and criteria for
IgG antibody seroconversiona
Assay (unit)
Sample
Criteria for seroconversionNegative Positive
MIF (titre)
IgG <32 ‡32 ‡4-fold titre increase
IgM <16 ‡16
EIA (EIU)
IgG <30b >45 If <130, ‡1.5-fold increase
If >130, ‡1.3-fold increase
IgM <1.1b >1.1
rELISA (cut-off index)c
IgG <0.9b >1.1 ‡3-fold increase
IgM <0.85b >1.15
MIF, microimmunoﬂuorescence; EIA, enzyme immunoassay; rELISA, recombinant
ELISA; EIU, enzyme immunounits.
aCut-off values and criteria for seroconversion are according to the manufac-
turers’ recommendations.
bFor the computation, all intermediate values (‘grey zone’) were considered to
be negative.
cCut-off index deﬁned as ODsample/ODcut-off.
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Two of these cases became positive by seroconversion only.
Seroconversion found with the combination of MIF and EIA
IgG was observed in four cases and considered to be nega-
tive. The seroconversion-positive samples were taken with a
median interval from the start of symptoms of 37 days
FIG. 2. Results of PCR, IgM antibody assays and IgG seroconversion
in relation to timing of sampling after onset of acute respiratory
Chlamydophila pneumoniae infection. Data from 41 positive cases
(date of sampling missing, n = 7). A case was deﬁned as
C. pneumoniae-positive if (i) the nasopharyngeal sample was PCR-
positive and/or the serum sample was positive (ii) in ‡2
C. pneumoniae IgM antibody assays and/or (iii) with respect to IgG
seroconversion. The total number of specimens for each time period
is presented above the bars.
TABLE 2. Outcome of different
combinations of tests during an
outbreak of Chlamydophila
pneumoniae infection
No. of positive tests Combination of tests
No. of
subjects
Accumulated
cases
5 PCR, IgM (MIF, EIA, rELISA), serocon versiona 5
No. of ﬁve positive tests 5 5
4 PCR, IgM (MIF, EIA, rELISA) 19
4 IgM (MIF, EIA, rELISA), seroconversion 1
4 PCR, IgM (EIA, rELISA), seroconversion 1
No. of four positive tests 21 26
3 IgM (MIF, EIA, rELISA) 8
3 PCR, IgM (MIF, rELISA) 1
3 PCR, IgM (EIA, rELISA) 1
3 IgM (EIA, rELISA), seroconversion 1
No. of three positive tests 11 37
2 PCR, seroconversion, (rELISA IgM)b 2
2 IgM (MIF, rELISA) 1
2 IgM (EIA, rELISA) 2
No. of two positive tests 5 42
1 PCR 2
1 PCR, (MIF/EIA IgM)b 1
1 PCR, (EIA IgM)b 1
1 Seroconversion, (rELISA IgM)b 1
1 Seroconversion 1
No. of one positive testc 6 48
0 MIF, EIA 1
0 MIF 2
0 EIA 2
0 rELISA 7
No. of one reactive testd 12 60
No. of reactived and negative tests 67
No. of all tests 127
MIF, microimmunoﬂuorescence test; EIA, enzyme immunoassay; rELISA, recombinant ELISA.
aIgG seroconversion is considered as ‘one test’ in this table.
bReactive assays deﬁned as negative (in parenthesis).
cPositive cases according to the deﬁnition.
dNegative cases according to the deﬁnition.
TABLE 3. Sensitivity, speciﬁcity and positive predictive
value (PPV) of three Chlamydophila pneumoniae IgM
antibody assays and IgG seroconversion, with the
C. pneumoniae PCR assay as reference standard
Sensitivity (%) Speciﬁcity (%) PPV (%)
MIF IgM 26/33 (79) 81/94 (86) 26/39 (67)
EIA IgM 28/33 (85) 79/94 (84) 28/43 (65)
rELISA IgM 29/33 (88) 73/94 (78) 29/50 (58)
IgM (‡2 positive) 27/33 (82) 81/94 (86) 27/40 (68)
IgG seroconversion 8/33 (24) 90/94 (96) 8/12 (67)
IgM (‡2 positive)
and/or IgG
seroconversion
29/33 (88) 79/94 (84) 29/44 (66)
n = 127; MIF, microimmunoﬂuorescence test; EIA, enzyme immunoassay;
rELISA, recombinant ELISA.
TABLE 4. Sensitivity, speciﬁcity and positive predictive
value (PPV) of the Chlamydophila pneumoniae PCR assay
and IgG seroconversion, with C. pneumoniae IgM assays (‡2
positive) as a reference standard
Sensitivity (%) Speciﬁcity (%) PPV (%)
PCR 27/40 (68) 81/87 (93) 27/33 (81)
IgG seroconversion 8/40 (20) 83/87 (95) 8/12 (67)
n = 127.
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(range 7–70 days) (Fig. 2). This accounted for a difference
between IgM-positive and IgG seroconversion-positive
samples, although not a signiﬁcant difference. rELISA IgG
alone revealed seroconversion in another 13 cases. In this
group, the median time after onset of illness was only
17 days. In contrast, using MIF and EIA, IgG seroconversion
was seen in one and four cases, respectively.
IgM and IgG antibody prevalence
Of the 79 conscripts who were negative according to PCR
and remained negative according to the IgM antibody refer-
ence standard assay and IgG seroconversion during the out-
break, 26 (33%) seemed to be protected, exhibiting two or
three positive results according to IgG antibody assays
before the outbreak. In contrast, only four (8%) of the 48
conscripts who yielded positive outbreak samples according
to the deﬁnition were IgG-positive before the outbreak.
Discussion
During an outbreak of acute respiratory tract infection in a
military community, an in-house PCR procedure and three
commercial C. pneumoniae IgM and IgG antibody assays were
evaluated with the participation of 127 conscripts. The naso-
pharyngeal samples from 33 (26%) subjects were PCR-posi-
tive, and ‡2 IgM antibody assays were positive for 40 (31%)
of them. IgG seroconversion was observed in only 12 sub-
jects. The sensitivity of the PCR-based assay was signiﬁcantly
higher if the sampling was performed during the ﬁrst weeks
of illness (Figs 2 and 3). All together, 48 cases were positive
on the basis of PCR and/or ‡2 IgM antibody assay and/or
IgG seroconversion results; among these, 24 cases (50%)
were positive on the basis of PCR and all three IgM assays.
The main ﬁnding of this study is that agreement between
the IgM tests is good, and that the EIA IgM test in particular
had both high sensitivity and speciﬁcity. The agreement [21]
between PCR and the MIF and EIA IgM antibody assays was
good, but the agreement between the IgM antibody assays
was better than that between PCR and the IgM assays.
The sensitivity of PCR was lower than that of any IgM
assay. Generally, PCR results are inﬂuenced by the sampling
technique, transport conditions, PCR equipment, assay condi-
tions and inhibitory substances. The lower sensitivity of PCR
observed during the later stages of infection may be
explained by clearance of the organism following antibiotic
treatment [8], as the majority of the test-positive group had
received macrolide treatment before sampling. The PCR-
based detection of C. pneumoniae demonstrated high speciﬁ-
city in this study. Only two subjects, from whom samples
were taken shortly after disease onset on days 11 and 14
without evidence of IgM and IgG seroreactivity, were posi-
tive according to PCR alone. One of them was IgG-positive
before and during the outbreak and may have been rein-
fected.
The speciﬁcity of nested PCR has been questioned, and
false-positive results due to contamination or amplicon car-
ryover have been reported [22]. Great care has been taken
to avoid contamination in this in-house nested PCR proce-
dure. Few C. pneumoniae-positive samples were reported by
the laboratory elsewhere in the region before, during or
after the outbreak [20]. This study does not conﬁrm earlier
reports that demonstrated, using PCR, a high rate of
C. pneumoniae carriage in healthy or sick subjects [3], mainly
children, without serological evidence of infection [23].
Whether bacteria are detected or not may depend on the
actual endemic situation.
A surprisingly large number of subjects who were IgM
antibody-positive within the ﬁrst weeks of illness was
observed, as in other studies [24]. This is a shorter period
than expected for an IgM antibody response [14]. This may
be due in part to the conscripts’ and the doctors’ difﬁculties
in distinguishing C. pneumoniae infection from the many other
respiratory infections often occurring in military camps [25].
The time of onset of illness is uncertain under such circum-
stances. The acute C. pneumoniae infection often shows a
biphasic pattern with a protracted course [26], which may
delay the ﬁrst consultation and makes determination of the
real onset of illness difﬁcult.
FIG. 3. Cumulative sensitivity of Chlamydophila pneumoniae PCR and
IgM antibody assays in relation to timing of sampling after onset of
acute respiratory C pneumoniae infection. Data from 41 positive
cases (missing data, n = 7). A case was deﬁned as C. pneumoniae
positive if (i) the nasopharyngeal sample was PCR-positive and/or the
serum sample was positive (ii) in ‡2 C. pneumoniae IgM antibody
assays and/or (iii) with respect to IgG seroconversion. The lines
intersect at 5 weeks.
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Only two of 48 positive cases were positive according to
seroconversion alone. The duration from onset of illness to
sampling may have been too short for the IgG antibody to
reach seroconversion levels. Overall, IgM antibody assays
and/or IgG serology have high sensitivity and speciﬁcity
(Table 3).
This study showed that the MIF test is less sensitive than
rELISA, which is reported to be less speciﬁc [11,15]. Detec-
tion of IgM antibodies contributed more to the diagnosis of
acute C. pneumoniae infection than previously reported.
Among PCR-positive subjects, Boman et al. found 39% of the
subjects to be IgM antibody-positive using MIF when only
one acute-phase serum sample, taken simultaneously with
the upper respiratory tract sample for PCR, was analysed
[7]. If a single IgM antibody test had been relied upon solely,
the diagnosis of acute infection according to the study deﬁni-
tion would have been made in 79%, 85% and 88% of the
cases using MIF, EIA and rELISA, respectively. These results
are unlikely to have been due to an ‘overdiagnosis’ of IgM
antibody-positive samples, given the fact that all samples
were deﬁned as IgM antibody-negative before the outbreak.
Comparison of an assay with a reference standard with
inverse time-dependent results, such as comparison of PCR
and serology, is unsatisfactory. Alternatively, the sensitivity
and speciﬁcity of the IgM antibody assays could have been
based on comparison with each other or with the MIF test,
the recognized method of choice [5,7,15]. Aside from techni-
cal aspects and the subjective MIF reading, the long delay
with which seropositivity occurs is a major drawback, causing
assay results obtained in the early phase to be labelled ‘false-
positive’ (Fig. 1).
The conclusion of an assay evaluation study depends on
the choice of the reference standard, and when the refer-
ence standard and the test assay demonstrate inverse
dynamics, the deﬁnitive result is also determined by the tim-
ing of sampling. Surprisingly, timing of sampling is seldom
reported in papers when reference standards are discussed.
In summary, PCR-based detection of nasopharyngeal
C. pneumoniae was more speciﬁc but less sensitive than that
based on speciﬁc IgM antibody analysis, and IgG seroconver-
sion contributed less to the diagnosis than expected. This
study involving military conscripts during a C. pneumoniae
outbreak demonstrates the importance of the timing of sam-
pling when comparing PCR and serological techniques.
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